Nothing Special   »   [go: up one dir, main page]

Dijkman et al., 1986 - Google Patents

Antileukoprotease in sputum during bronchial infections

Dijkman et al., 1986

Document ID
12647586751957817110
Author
Dijkman J
Kramps J
Franken C
Publication year
Publication venue
Chest

External Links

Snippet

Production of sputum and concentrations of antileukoprotease (ALP) in sputum were serially measured in hypersecreting patients with recurrent or chronic bronchial infections. Patients with stable continuous mucoid (n= 4) or purulent (n= 5) secretions had constant sputum …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors

Similar Documents

Publication Publication Date Title
Tsang et al. Sputum elastase in steady-state bronchiectasis
Bergin et al. Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
Vignola et al. Increased levels of elastase and α1-antitrypsin in sputum of asthmatic patients
Mallia et al. Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease
Light et al. Diagnostic significance of pleural fluid pH and PCO2
Lieberman Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data
Kyndt et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis
Del Donno et al. The effect of inflammation on mucociliary clearance in asthma: an overview
Palmer et al. Aerosolized antibiotics in mechanically ventilated patients: delivery and response
Fujimoto et al. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema
Crooks et al. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4
Fahya et al. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation
Pressler et al. Chronic Pseudomonas aeruginosa infection definition: EuroCareCF working group report
Roberts et al. Relationship between chronic nasal and respiratory symptoms in patients with COPD
Nseir et al. Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory failure: a case–control study
Shah et al. Determinants of chronic infection with Staphylococcus aureus in patients with bronchiectasis
Ashitani et al. Plasma and BAL fluid concentrations of antimicrobial peptides in patients with Mycobacterium avium-intracellulare infection
Corhay et al. Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD
App et al. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis
Puchelle et al. Effects of rhDNase on purulent airway secretions in chronic bronchitis
Stockley et al. Relationship of neutrophil cytoplasmic protein (L1) to acute and chronic lung disease
Kim et al. Sputum processing for evaluation of inflammatory mediators
JETT et al. Plastic bronchitis: an old disease revisited
Gulcan et al. Cyanocobalamin may be beneficial in the treatment of recurrent aphthous ulcers even when vitamin B12 levels are normal
Dijkman et al. Antileukoprotease in sputum during bronchial infections